SGLT2 Inhibitors role in Heart Failure: More Than Just Glycemic Control

Authors

  • Emman Memon Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, Pakistan Author

DOI:

https://doi.org/10.63501/zqz05q25

Abstract

Not applicable

References

1. Darwish D, Kumar P, Urs K, Dave S. Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure. Cells. 2025;14(12):919. doi:10.3390/cells14120919.

2. Rauf U, Ansar F, Ali MS, Chudhary F, Zafar MH, Azzam A, et al. Effect of Empagliflozin on Cardiovascular Mortality and Heart Failure Hospitalizations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2025;17(6):e85669. doi:10.7759/cureus.85669.

3. Albulushi A, Askari KM, Al-Abedi AM, et al. Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study. Eur J Med Res. 2025;30(1):592. doi:10.1186/s40001-025-02834-7.

4. Li J, Wang X, Zheng Q, Tian J, Chen H, Yao S. Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study. BMC Cardiovasc Disord. 2025;25(1):485. doi:10.1186/s12872-025-04952-w.

5. Santos Guzmán MV, Rivera D, Reyna Guerrero IM, et al. Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review. Cureus. 2025;17(5):e84129.

Downloads

Published

2025-09-25

Issue

Vol. 1 No. 3 (2025): Fall

Section

⁠Letters to the Editor

License

This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given to the author(s) and the source. To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0